最終更新日：2025/11/21
The new agonistic monoclonal antibody showed promising results in early trials by enhancing T-cell responses against tumors.
正解を見る
The new agonistic monoclonal antibody showed promising results in early trials by enhancing T-cell responses against tumors.
音声機能が動作しない場合はこちらをご確認ください
編集履歴（0）
